Update on Opsoclonus–Myoclonus Syndrome in Adults

Total Page:16

File Type:pdf, Size:1020Kb

Update on Opsoclonus–Myoclonus Syndrome in Adults Journal of Neurology (2019) 266:1541–1548 https://doi.org/10.1007/s00415-018-9138-7 NEUROLOGICAL UPDATE Update on opsoclonus–myoclonus syndrome in adults Sun‑Young Oh1,2 · Ji‑Soo Kim3,4 · Marianne Dieterich5,6,7 Received: 31 August 2018 / Revised: 17 November 2018 / Accepted: 21 November 2018 / Published online: 27 November 2018 © Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Opsoclonus–myoclonus syndrome in adults is a rare and heterogeneous disorder with the clinical features of opsoclonus, myoclonus, ataxia, and behavioral and sleep disturbances. The pathophysiology is thought to be immunological on the basis of paraneoplastic or infectious etiologies. Immunomodulatory therapies should be performed although the response may be incomplete. A number of autoantibodies have been identified against a variety of antigens, but no diagnostic immunological marker has yet been identified. This review focuses on underlying mechanisms of opsoclonus–myoclonus syndrome, including findings that have been identified recently, and provides an update on the clinical features and treatments of this condition. Keywords Opsoclonus–myoclonus syndrome · Autoimmune · Encephalitis · Paraneoplastic · Antibodies Introduction disturbances, cognitive impairments, and behavioral disrup- tion. The etiology of OMS in adults varies and includes par- Opsoclonus–myoclonus syndrome (OMS) is a disorder that aneoplastic, parainfectious, toxic-metabolic, and idiopathic classically causes opsoclonus which consists of bursts of causes. Humoral and cell-mediated immune mechanisms high-frequency oscillations of the eyes with horizontal, ver- have both been implicated and a variety of paraneoplastic tical, and torsional saccades as well as myoclonus (nonepi- and cell surface autoantibodies have been detected. Para- leptic involuntary jerks of the limbs and trunk) and ataxia neoplastic OMS [2] is usually observed in pediatric patients [1]. Affected patients may suffer from oscillopsia (illusory with neuroblastoma [3] or in adult patients with antineuronal motion of the visual world) and vertigo as well as sleep nuclear antibody type 2 (ANNA-2, anti-Ri) accompanying breast adenocarcinoma [4] or small cell lung cancer (SCLC) [5]. However, the majority of patients with OMS are seron- * Sun-Young Oh [email protected] egative for all known antineuronal antibodies [6]. In this review, the clinical and immunological features, 1 Department of Neurology, Chonbuk National University pathogenesis and treatment options for OMS in adults are School of Medicine, 20 Geonji-ro, Deokjin-gu, Jeonju, summarized with a particular focus on recent advances in Chonbuk 561-712, South Korea our understanding of OMS pathophysiology based on immu- 2 Research Institute of Clinical Medicine of Chonbuk National nologic and neuroimaging studies. University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, South Korea 3 Department of Neurology, Seoul National University College Clinical presentation of Medicine, Seoul, South Korea 4 Department of Neurology, Dizziness Center, Clinical Neuroscience Center, Seoul National University Bundang Opsoclonus consists of back-to-back multidirectional con- Hospital, Seongnam, South Korea jugate saccades without an inter-saccadic interval, with an 5 Department of Neurology, Ludwig-Maximilians-University, amplitude ranging from 18° to 58° and a rate of 10–25 Hz Munich, Germany [1]. Ocular flutter shares the same properties as opsoclonus, 6 German Center for Vertigo and Balance Disorders but is limited to one plane, usually horizontal saccades with (IFBLMU), Ludwig-Maximilians University, Munich, varying amplitudes. The term ‘opsoclonus–myoclonus syn- Germany drome’ refers to continuous opsoclonus that is accompanied 7 Munich Cluster for Systems Neurology (SyNergy), Munich, by ataxia, encephalopathy, and myoclonus [1]. Although Germany Vol.:(0123456789)1 3 1542 Journal of Neurology (2019) 266:1541–1548 opsoclonus and myoclonus are the most distinctive signs, because of the issue of atypical presentations of the disorder, they may be absent [7, 8]. In one study, about 20% of OMS we introduced diagnostic criteria for OMS which had previ- patients had atypical presentations with a delayed onset of ously been proposed by an expert panel [14]; the diagnosis opsoclonus and marked asymmetry of ataxia for which they of OMS should be made when three of four features are pre- can be misdiagnosed as having a cerebellar ataxia or epi- sent: opsoclonus, myoclonus or ataxia, behavioral changes leptic seizures [2]. Other, related clinical presentations that or sleep disturbances, and tumorous conditions or presence should be recognized as possibly paraneoplastic include of antineuronal antibodies (Table 1). opsoclonus only [9], or without opsoclonus, progressive encephalomyelitis with rigidity and myoclonus [10], and iso- lated generalized small-amplitude limb and axial myoclonus Immunological features [11]. This latter group presents with myoclonus, but with- out opsoclonus and, therefore, may receive misdiagnosis as A recent clinical and immunologic study reported that OMS tremor or other paraneoplastic disorders. Diagnostic delays is paraneoplastic in 39% (45/114) and idiopathic in 61% can be problematic; in previous studies, the average diag- of cases (69/114) (Fig. 1) [6]. Humoral and cell-mediated nostic delay from symptom onset was 11 weeks [12, 13]. In immune mechanisms have both been implicated in paraneo- patients with delay in diagnosis of more than 2 months, there plastic and idiopathic OMS [15]. A number of autoantibod- have been consistent trends towards worse neurological, neu- ies have been associated with paraneoplastic OMS includ- ropsychological, and behavioral outcomes [13]. Therefore, ing antibodies against Ri (ANNA-2) [16], Hu (ANNA-1) [17], Yo (PCA-1) [18], Ma1 [19], Ma2 [19, 20], N-methyl- D-aspartate (NMDA) receptor [21], amphiphysin [22, 23], Table 1 Proposed diagnostic criteria for opsoclonus myoclonus syn- CRMP-5/anti-CV2 [24], Zic2 [25], and neurofilaments [26]. drome (OMS) In patients with paraneoplastic OMS, small cell lung cancer At least three of four supportive findings (SCLC), breast carcinoma, and ovarian teratoma were the Opsoclonus most frequent neoplasms identified. Onconeuronal antibod- Myoclonus and/or ataxia ies occurred in 11% of patients, mostly Ri/ANNA2 anti- Behavioral change and/or sleep disturbance bodies, which were detected in 70% of patients with breast Tumorous conditions and/or presence of antineuronal antibodies cancer [27–29]. Neuronal surface antibodies, mainly glycine Fig. 1 Clinical assessment of opsoclonus myoclonus syndromes. Ab antibody, FDG PET fluorodeoxyglucose positron emission tomography, TAP-CT thoraco-abdomino-pelvic computed tomography 1 3 Journal of Neurology (2019) 266:1541–1548 1543 receptor antibodies, were identified in 11% of patients, most Furthermore, treatments such as corticosteroids or intra- of whom had paraneoplastic OMS with lung cancer. Other venous immunoglobulin (IVIG) alone or combined with oncologic associations include neoplasms of the gynecologic antimicrobial therapy are usually successful. This suggests [30–34], urologic [28, 35], hematologic [36] and gastroin- that an infectious process may play a role in activating the testinal systems [29], and melanoma [37, 38]. A novel cell immunological system in this condition in some patients [9, surface epitope, human natural killer 1 (HNK-1), was also 55, 61, 62]. the target of the antibodies in 3 patients with lung cancer One study revealed that parents of children with OMS and paraneoplastic OMS [6]. However, these paraneoplastic (15.8%) report an autoimmune disorder more frequently, intracellular antibodies, including anti-Ri and anti-Hu anti- including autoimmune thyroid disease, rheumatoid arthritis, body, and antibodies against the cell surface NMDA recep- systemic lupus erythematosus, and type 1 insulin-dependent tor, have rarely been identified in patients with OMS despite diabetes, compared with control parents (2%) [63]. Although comprehensive serologic evaluations [21, 23, 39, 40]. Fur- these intriguing findings support the idea of genetic predis- thermore, the diversity of reported paraneoplastic autoanti- position in OMS, the specific genes involved have not yet bodies, including those with specificity for other neuronal been identified. Rarely nonparaneoplastic and nonparainfec- nuclear antigens [29, 41], NMDA receptors [21, 42], and tious autoimmune OMS have been reported in association neuronal calcium channels [43, 44], serves to emphasize with GAD65 antibody-associated OMS [64] and pregnancy- the importance of comprehensive paraneoplastic serological related OMS mimicking chorea gravidarum [65]. These are evaluations rather than syndrome-specific physician-selected similarly responsive to immunotherapy [66]. antibody testing in OMS patients. Therefore, at present, though useful in selected cases, none of these autoantibod- ies appear to be sensitive for the majority of OMS patients. Pathogenesis In addition to serum autoantibodies against neuronal tis- sues in patients with OMS, other pieces of evidence for an As the eye movements in opsoclonus or ocular flutter are autoimmune process include the presence of B-cell acti- saccadic in origin, an early hypothesis was that opsoclonus vating factor (BAFF), which is a key molecule involved in is due to damage of the omnipause neurons (OPN) in the B-cell survival [45], in the serum and cerebrospinal fluid of nucleus raphe interpositus
Recommended publications
  • Research Experiences Research Is an Important Part of the Training of Child Neurology Residents at Children’S Mercy Hospital
    Research Experiences Research is an important part of the training of Child Neurology residents at Children’s Mercy Hospital. Training in research starts with the research mentor that each resident is encouraged to engage at the beginning of their child neurology training. The residents are also invited to complete a course on biostatistics and each resident is expected to complete a 1 year course in Quality Improvement and Clinical Safety. As part of the QI course each resident will initiate a QI project which can be presented at CMH Research Day. Each resident is also given the opportunity to present at the yearly Missouri Valley Child Neurology Colloquium. This is a joint meeting with The University of Washington and Saint Louis University Child Neurology programs. Finally, each resident is expected to graduate with at least one first author publication. Over the last 4 years our residents have given over 100 talks (with approximately 20% of these original research or case presentations) and have published 13 papers in peer reviewed journals (including original research and review papers). Faculty Program Director Jean-Baptiste (J.B.) Le Pichon, MD, PhD: Dr. Le Pichon was born in New York City but grew up in France. He completed his undergraduate education at Gannon University, Erie Pennsylvania followed by an MD/PhD program at Baylor College of Medicine, Houston Texas. Dr. Le Pichon completed his PhD in neuroscience. Following medical school, he completed two years of Pediatrics at Driscoll Children’s Hospital in Corpus Christi and then completed a Child Neurology Residency at Texas Children’s Hospital.
    [Show full text]
  • Myoclonus Aspen Summer 2020
    Hallett Myoclonus Aspen Summer 2020 Myoclonus (Chapter 20) Aspen 2020 1 Myoclonus: Definition Quick muscle jerks Either irregular or rhythmic, but always simple 2 1 Hallett Myoclonus Aspen Summer 2020 Myoclonus • Spontaneous • Action myoclonus: activated or accentuated by voluntary movement • Reflex myoclonus: activated or accentuated by sensory stimulation 3 Myoclonus • Focal: involving only few adjacent muscles • Generalized: involving most or many of the muscles of the body • Multifocal: involving many muscles, but in different jerks 4 2 Hallett Myoclonus Aspen Summer 2020 Differential diagnosis of myoclonus • Simple tics • Some components of chorea • Tremor • Peripheral disorders – Fasciculation – Myokymia – Hemifacial spasm 9 Classification of Myoclonus Site of Origin • Cortex – Cortical myoclonus, epilepsia partialis continua, cortical tremor • Brainstem – Reticular myoclonus, exaggerated startle, palatal myoclonus • Spinal cord – Segmental, propriospinal • Peripheral – Rare, likely due to secondary CNS changes 10 3 Hallett Myoclonus Aspen Summer 2020 Classification of myoclonus to guide therapy • First consideration: Etiological classification – Is there a metabolic encephalopathy to be treated? Is there a tumor to be removed? Is a drug responsible? • Second consideration: Physiological classification – Can the myoclonus be treated symptomatically even if the underlying condition remains unchanged? 12 Myoclonus: Physiological Classification • Epileptic • Non‐epileptic The basic question to ask is whether the myoclonus is a “fragment
    [Show full text]
  • Motor Neuron Disease (Amyotrophic Lateral Sclerosis) Arising from Longstanding Primary Lateral Sclerosis
    74274ournal ofNeurology, Neurosurgery, and Psychiatry 1995;58:742-744 SHORT REPORT J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.58.6.742 on 1 June 1995. Downloaded from Motor neuron disease (amyotrophic lateral sclerosis) arising from longstanding primary lateral sclerosis R P M Bruyn, J H T M Koelman, D Troost,J M B V de Jong Abstract family history was negative and consanguinity Three men were initially diagnosed as was excluded. Examination disclosed slight having primary lateral sclerosis (PLS), weakness of the left thigh muscles, mild spas- but eventually developed amyotrophic ticity of the legs, knee and ankle cloni, and lateral sclerosis (ALS) after 7-5, 9, and at extensor plantars. Blood chemistry, CSF, and least 27 years. Non-familial ALS and EMG were unremarkable. Magnetic reso- PLS might be different manifestations of nance imaging of the cervical spine was nor- a single disease or constitute completely mal and PLS was diagnosed. Micturition distinct entities. The clinical diagnosis of urgency began in 1987. Examination in 1988 PLS predicts a median survival that is showed definite spastic paraparesis and mild four to five times longer than in ALS. proximal weakness of the legs. Sural and tib- ial nerve somatosensory evoked potentials (J Neurol Neurosurg Psychiatry 1995;58:742-744) (SSEPs) were bilaterally absent and delayed respectively. Visual and brainstem auditory evoked potentials (VEPs, BAEPs), and brain Keywords: amyotrophic lateral sclerosis; primary MRI were normal. By 1990, walking had lateral sclerosis become troublesome and dysarthria was pre- sent; the calves showed fasciculation and Primary lateral sclerosis (PLS), defined as some atrophy.
    [Show full text]
  • The Serotonin Syndrome
    The new england journal of medicine review article current concepts The Serotonin Syndrome Edward W. Boyer, M.D., Ph.D., and Michael Shannon, M.D., M.P.H. From the Division of Medical Toxicology, he serotonin syndrome is a potentially life-threatening ad- Department of Emergency Medicine, verse drug reaction that results from therapeutic drug use, intentional self-poi- University of Massachusetts, Worcester t (E.W.B.); and the Program in Medical Tox- soning, or inadvertent interactions between drugs. Three features of the sero- icology, Division of Emergency Medicine, tonin syndrome are critical to an understanding of the disorder. First, the serotonin Children’s Hospital, Boston (E.W.B., M.S.). syndrome is not an idiopathic drug reaction; it is a predictable consequence of excess Address reprint requests to Dr. Boyer at IC Smith Bldg., Children’s Hospital, 300 serotonergic agonism of central nervous system (CNS) receptors and peripheral sero- 1,2 Longwood Ave., Boston, MA 02115, or at tonergic receptors. Second, excess serotonin produces a spectrum of clinical find- [email protected]. edu. ings.3 Third, clinical manifestations of the serotonin syndrome range from barely per- This article (10.1056/NEJMra041867) was ceptible to lethal. The death of an 18-year-old patient named Libby Zion in New York updated on October 21, 2009 at NEJM.org. City more than 20 years ago, which resulted from coadminstration of meperidine and phenelzine, remains the most widely recognized and dramatic example of this prevent- N Engl J Med 2005;352:1112-20. 4 Copyright © 2005 Massachusetts Medical Society. able condition.
    [Show full text]
  • The Clinical Approach to Movement Disorders Wilson F
    REVIEWS The clinical approach to movement disorders Wilson F. Abdo, Bart P. C. van de Warrenburg, David J. Burn, Niall P. Quinn and Bastiaan R. Bloem Abstract | Movement disorders are commonly encountered in the clinic. In this Review, aimed at trainees and general neurologists, we provide a practical step-by-step approach to help clinicians in their ‘pattern recognition’ of movement disorders, as part of a process that ultimately leads to the diagnosis. The key to success is establishing the phenomenology of the clinical syndrome, which is determined from the specific combination of the dominant movement disorder, other abnormal movements in patients presenting with a mixed movement disorder, and a set of associated neurological and non-neurological abnormalities. Definition of the clinical syndrome in this manner should, in turn, result in a differential diagnosis. Sometimes, simple pattern recognition will suffice and lead directly to the diagnosis, but often ancillary investigations, guided by the dominant movement disorder, are required. We illustrate this diagnostic process for the most common types of movement disorder, namely, akinetic –rigid syndromes and the various types of hyperkinetic disorders (myoclonus, chorea, tics, dystonia and tremor). Abdo, W. F. et al. Nat. Rev. Neurol. 6, 29–37 (2010); doi:10.1038/nrneurol.2009.196 1 Continuing Medical Education online 85 years. The prevalence of essential tremor—the most common form of tremor—is 4% in people aged over This activity has been planned and implemented in accordance 40 years, increasing to 14% in people over 65 years of with the Essential Areas and policies of the Accreditation Council age.2,3 The prevalence of tics in school-age children and for Continuing Medical Education through the joint sponsorship of 4 MedscapeCME and Nature Publishing Group.
    [Show full text]
  • The Effects of Reflex Path Length on Clonus Frequency in Spastic Muscles
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.47.10.1122 on 1 October 1984. Downloaded from Journal ofNeurology, Neurosurgery, and Psychiatry 1984;47:1122-1124 Short report The effects of reflex path length on clonus frequency in spastic muscles ROBERT IANSEK From the Department ofNeurology, Prince Henry's Hospital, Melbourne, Australia SUMMARY Clinical evaluation of clonus in spastic muscles was performed by comparing reflex path length with clonus frequency for different muscles in the same patient. It was found that clonus frequency varied inversely with reflex path length (r = 0-84, p < 0-001). The findings confirm that clonus is generated by a peripheral mechanism of self re-excitation rather than a central spinal pacemaker. Clonus is a well recognised clinical sign, usually Methods guest. Protected by copyright. occurring in spasticity. A normal, nonspastic limb may manifest clonus, but only under certain condi- Twenty-one unselected patients who were seen on the tions.' The repetitive self perpetuating movement is neurology service were used as subjects. Attempts were induced by brisk stretch of the involved muscle made to study patients with clonus in more than one mus- group, although cutaneous sensory inputs can initi- cle. No restriction was placed on the underlying pathologi- cal basis for the spasticity. Neurological examination and ate clonic movements in a susceptible limb.2 The routine nerve conduction studies were performed to underlying mechanism of clonus is poorly under- exclude an underlying neuropathy. Clonus frequency was stood and controversial. Some investigators34 have measured by use of surface electrodes and the raw EMG evidence to support the theory of a self re-excitation was recorded on photosensitive paper.
    [Show full text]
  • Spasticity in the Podiatric Patient
    CHAPTER II SPASTICITY IN TI{E PODIATRIC PATIENT Lwke D. Cicchinelli, DPM The management of the podiatric patient presenting with diseases at this level such as polio effect the classic lower spasticity can be both vexing and rewarding. Content with a motor neuron syndrome. seemingly good outcome at 1 year postoperarively must be This lower motor neuron condition exhibits in tempered wit-h an appreciation for the potential conse- general that individual muscles may be affected, atrophy quences of a growing limb and the complex interplay is pronounced as the muscles do not receive normal between muscles, tendons and osseous factors. The 10 year innervation, flaccidiry and hypotonia of affected muscles follow up outcome might be very different and the patient with loss of tendon reflexes, plantar or babinski reflex if may have other as yet unrecognized functional aberrations. present is of the normal or flexor type, fasciculations may So how does one treat rhese patients? Many be present representing the sporadic discharge of questions come to mind. Do you transfer a spastic muscle fibers due to diseased and irritable axons and muscle? Is the neuromuscular lesion static or progressive? electromyograms reveal reduced numbers of motor units You are a podiatrist, what about the suprastructural and fibrillations representing isolated activity of individ- deformity such as spastic hip adductors, whar is their affect ual muscle fibers. Sensorium is intact. No clonus is on the lower limb function? Is the foot reducible or rigid? Present. Diseases of lower motor neurons or peripheral \fill a muscle tendon transfer shift the muscle power rhe nerves show distal limb weaknesses such as foot drop or a wrong way causing a resultant different deformiry? Are the steppage gait.
    [Show full text]
  • Opsoclonus-Myoclonus Presenting with Features of Spasmus Nutans
    67 References scans of the brain were normal, and cerebrospinal fluid was acellular, 1. Balk R, Hiller C, Lucas EA, et al: Sleep apnea and the Arnold Chiari with normal chemistries. A 24-hour urine collection revealed vanilmandel- malformation. Am Rev Respir Dis 1985;132:929-930. ic acid, 1.9 mg/total volume (normal, 1 to 1.5 mg); homovanillic acid, 1.4 2. Ruff ME, Oakes WJ, Fisher SR, Spock A: Sleep apnea and vocal mg/total volume (normal, 0 to 4 mg); homovanillic acid/creatinine ratio, cord paralysis secondary to type I Chiari malformation. Pediatrics 17 mg/g of creatinine (normal, < 35 mg/g); epinephrine, 7.0 ug/tota.l volume 1987;80:231-234. (normal, 0 to 5.0 ug); and norepinephrine, 8.0 ug/total volume (normal, 0 3. Levitt P, Cohen MA: Sleep apnea and the Chiari I malformation: to 20 ug). Chest and abdominal computed tomographic and radiolabeled Case report. Neurosurgery 1988;23:508-510. metaiodobenzylguanidine scan did not show neuroblastoma. 4. Langevin B, Sukkar F, Leger P, et al: Sleep apnea syndromes (SAS) The child’s head tremor worsened over the ensuing 2 weeks to the of specific etiology: Review and incidence from a sleep laboratory. point of interfering with her sleep. Her parents now noted large involun- Sleep 1992;15:S25-S32. tary eye movements, increasing unsteadiness, and rapid jerking of the 5. White DP: Central sleep apnea, in Kryger MH, Roth T, Dement WC extremities that interrupted her attempts at feeding. Examination (eds): Principles and Practice of Sleep Medicine. Philadelphia, WB showed rapid, continuous horizontal, vertical, and oblique conjugate eye Saunders, 1989, pp 513-524.
    [Show full text]
  • Autoimmune Disorders and Paraneoplastic Syndromes in Thymoma
    7590 Review Article on Thymoma Autoimmune disorders and paraneoplastic syndromes in thymoma Torsten Gerriet Blum, Daniel Misch, Jens Kollmeier, Sebastian Thiel, Torsten T. Bauer Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany Contributions: (I) Conception and design: TG Blum; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: TG Blum; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: TG Blum; (VII) Final approval of manuscript: All authors. Correspondence to: Dr. Torsten Gerriet Blum. Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Walterhöferstr. 11, 14165 Berlin, Germany. Email: [email protected]. Abstract: Thymomas are counted among the rare tumour entities which are associated with autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other malignancies. Through its complex immunological function in the context of the selection and maturation of T cells, the thymus is at the same time highly susceptible to disruptive factors caused by the development and growth of thymic tumours. These T cells, which are thought to develop to competent immune cells in the thymus, can instead adopt autoreactive behaviour due to the uncontrolled interplay of thymomas and become the trigger for AID or PNS affecting numerous organs and tissues within the human body. While myasthenia gravis is the most prevalent PNS in thymoma, numerous others have been described, be they related to neurological, cardiovascular, gastrointestinal, haematological, dermatological, endocrine or systemic disorders. This review article sheds light on the pathophysiology, epidemiology, specific clinical features and therapeutic options of the various forms as well as courses and outcomes of AID/PNS in association with thymomas.
    [Show full text]
  • Acute Inflammatory Myelopathies
    UCSF UC San Francisco Previously Published Works Title Acute inflammatory myelopathies. Permalink https://escholarship.org/uc/item/3wk5v9h9 Journal Handbook of clinical neurology, 122 ISSN 0072-9752 Author Cree, Bruce AC Publication Date 2014 DOI 10.1016/b978-0-444-52001-2.00027-3 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Handbook of Clinical Neurology, Vol. 122 (3rd series) Multiple Sclerosis and Related Disorders D.S. Goodin, Editor Copyright © 2014 Bruce Cree. Published by Elsevier B.V. All rights reserved Chapter 28 Acute inflammatory myelopathies BRUCE A.C. CREE* Department of Neurology, University of California, San Francisco, USA INTRODUCTION injury caused by the acute inflammation and the likeli- hood of recurrence differs depending on the etiology. Spinal cord inflammation can present with symptoms sim- Additional important diagnostic and prognostic features ilar to those of compressive myelopathies: bilateral weak- include whether the myelitis is partial or transverse, ness and sensory changes below the spinal cord level of febrile illness, the number of vertebral spinal cord injury, often accompanied by bowel and bladder impair- segments involved on MRI at the time of acute attack, ment and sparing cranial nerve and cerebral function. the rapidity from symptom onset to maximum deficit, Because of the widespread availability of magnetic reso- and the severity of involvement. nance imaging (MRI) and computed tomography (CT) imaging, compressive etiologies can be rapidly excluded, METHODOLOGIC CONSIDERATIONS leading to the consideration of non-compressive etiologies for myelopathy. The differential diagnosis of non- Large observational cohort studies or randomized con- compressive myelopathy is broad and includes infectious, trolled trials concerning myelitis have never been under- parainfectious, toxic, nutritional, vascular, and systemic taken.
    [Show full text]
  • For Sick Children, Glasgow; Great Ormond Street Hospital, London; and Guy's and St Thomas Evelina Children's Hospital, London, UK
    MOVEMENT DISORDERS OUTCOME OF OPSOCLONUS-MYOCLONUS SYNDROME Long-term neurologic sequelae and predictors for disease outcome were identified in 101 patients diagnosed with opsoclonus-myoclonus syndrome (OMS) over a 53-year period at Royal Hospital for Sick Children, Glasgow; Great Ormond Street Hospital, London; and Guy's and St Thomas Evelina Children's Hospital, London, UK. Median age at disease onset was 18 months (range 3 months to 8.9 years). Neuroblastoma was detected in 21% of patients (40% in those born after 1990). A preceding illness was reported in 56 patients (upper respiratory tract infection, gastroenteritis, and nonspecific), and 8% had been vaccinated within one month of symptom onset. Treatment of OMS consisted of steroids in 87%, none in 12%, and IVIg in 1 case. Median follow-up was 7.3 years (range 3-32 years). Response was good in 35% and moderate in 60%. The course was chronic-relapsing in 61% patients and monophasic in 7%, and acute exacerbations were frequent in 32%. At last review, 60% had residual motor problems, 66% speech abnormalities, 51% learning disability, and 46% behavior problems. One third had normal intellectual outcome and were asymptomatic. A severe initial presentation in 82% patients predicted a chronic course and later learning disability. Cognitive impairment occurred in patients younger at disease onset. A chronic-relapsing course was associated with motor, speech, cognitive, and behavior problems. (Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics August 2011;128:e388-e394). (Respond: Andreas Brunklaus MD, Neurosciences Unit, Royal Hospital for Sick Children, Dalnair Street, Glasgow G3 8SJ, UK.
    [Show full text]
  • Increased Prevalence of Familial Autoimmune Disease in Children with Opsoclonus-Myoclonus Syndrome
    ARTICLE OPEN ACCESS Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome Jonathan D. Santoro, MD, Lauren M. Kerr, BA, Rachel Codden, MPH, Theron Charles Casper, PhD, Correspondence Benjamin M. Greenberg, MD, Emmanuelle Waubant, MD, PhD, Sek Won Kong, MD, Dr. Santoro [email protected] Kenneth D. Mandl, MD, MPH, and Mark P. Gorman, MD Neurol Neuroimmunol Neuroinflamm 2021;8:e1079. doi:10.1212/NXI.0000000000001079 Abstract Background and Objectives Opsoclonus-myoclonus syndrome (OMS) is a rare autoimmune disorder associated with neuroblastoma in children, although idiopathic and postinfectious etiologies are present in children and adults. Small cohort studies in homogenous populations have revealed elevated rates of autoimmunity in family members of patients with OMS, although no differentiation between paraneoplastic and nonparaneoplastic forms has been performed. The objective of this study was to investigate the prevalence of autoimmune disease in first-degree relatives of pediatric patients with paraneoplastic and nonparaneoplastic OMS. Methods A single-center cohort study of consecutively evaluated children with OMS was performed. Parents of patients were prospectively administered surveys on familial autoimmune disease. Rates of autoimmune disease in first-degree relatives of pediatric patients with OMS were compared using Fisher exact t test and χ2 analysis: (1) between those with and without a paraneoplastic cause and (2) between healthy and disease (pediatric multiple sclerosis [MS]) controls from the United States Pediatric MS Network. Results Thirty-five patients (18 paraneoplastic, median age at onset 19.0 months; 17 idiopathic, median age at onset 25.0 months) and 68 first-degree relatives (median age 41.9 years) were enrolled.
    [Show full text]